Drug Profile
Encapsulated cell therapy - IsoTis OrthoBiologics
Alternative Names: ECT - IsoTis OrthoBiologicsLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator StemCells
- Developer IsoTis OrthoBiologics; Novartis
- Class Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Anaemia; Solid tumours
Most Recent Events
- 28 Nov 2016 StemCells has been acquired by Microbot Medical
- 09 Nov 2005 No development reported - Phase-I for Anaemia in Switzerland (unspecified route)
- 09 Nov 2005 No development reported - Preclinical for Solid tumours in Switzerland (unspecified route)